HOME > TOP STORIES
TOP STORIES
-
REGULATORY BMS’s Sotyktu to Get 8.6% Price Cut in August after Cost-Effectiveness Assessment
May 16, 2024
-
REGULATORY Annual Price Revisions Should Continue in 2025 and Beyond: MOF Budget Examiner
May 15, 2024
-
BUSINESS As Latuda Sales Evaporate, Sumitomo Shakes Up Top Brass for Turnaround
May 15, 2024
-
BUSINESS Teva to Let Go of Japan Generic Business in 2025 but Denies Full Exit
May 15, 2024
-
ACADEMIA Researchers Crafting Japan’s 1st Guidelines for ALS Trials, Eye FY2026 Completion
May 14, 2024
-
BUSINESS Lilly’s Gemzar to Exit Japan Market Next Spring under G1 Withdrawal Rule
May 13, 2024
-
BUSINESS Moderna Set to Develop Cancer Vaccines, Rare Disease Therapies in Japan: New Local Chief
May 10, 2024
-
BUSINESS Lilly Japan Nets 10% Sales Rise in 2023, Eyes No. 1 Growth for Protected Medicines
May 9, 2024
-
BUSINESS Lilly Files Tirzepatide for Obesity in Japan, Ties Up with Mitsubishi
May 9, 2024
-
ACADEMIA Japan to Forge National Registry for Leqembi, Test Genes to Predict Side Effects
May 8, 2024
-
REGULATORY New LDP Project Team Boots Up for Healthcare Transformation
May 8, 2024
-
BUSINESS Jevtana Supply Crunch amid Demand Spike Already Affecting Patients in Japan
May 7, 2024
-
BUSINESS Sumitomo Sets Out for Reconstruction, Further Cost Cuts in FY2024
May 2, 2024
-
BUSINESS Regeneron Set for Commercial Expansion in Japan, Eyes Dupixent Ramp-Up
May 1, 2024
-
BUSINESS Celltrion Japan Unveils New List of 5 Biosimilars in Development; Actemra and Pralia and More
May 1, 2024
-
REGULATORY Japan’s 1st Eylea Biosimilar Now in Line for Approval, AMD Dropped for Patent Reasons
April 30, 2024
-
BUSINESS Janssen Primed to Join Japan Lung Cancer Market with Doublet Now under Review
April 26, 2024
-
REGULATORY Japan Plans More Prompt Drug Approvals from 2025, Within 3 Weeks of Panel Nod
April 25, 2024
-
BUSINESS Rakuten Medical Ratcheting Up Overseas Expansion Drive for Akalux: Japan Chief
April 25, 2024
-
BUSINESS Bayer Poised to Navigate Patent Cliff with Blockbuster Hopefuls for Stroke, Kidney Disease
April 24, 2024
ページ
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
